Cibus (CBUS) Change in Account Payables (2016 - 2025)
Cibus (CBUS) posted Change in Account Payables of $510000.0 for Q4 2025, up 298.44% sequentially from $128000.0 in Q3 2025, and up 149.71% YoY from $204238.9 in Q4 2024.
Cibus (CBUS) Change in Account Payables (2016 - 2025) Analysis & Trends
Cibus has reported Change in Account Payables for 10 years, with the latest figure at $510000.0 in Q4 2025.
- Quarterly Change in Account Payables rose 149.71% year-over-year to $510000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $720000.0 (up 482.98% YoY) and the FY2025 annual result came in at $720000.0, up 482.98% from the prior year.
- Change in Account Payables advanced to $510000.0 in Q4 2025 per CBUS's latest filing, from $128000.0 in the prior quarter.
- Over five years, Change in Account Payables peaked at $2.2 million in Q3 2023 and troughed at -$2.3 million in Q2 2023.
- A 5-year average of -$2750.0 and a median of $8500.0 in 2021 frame the typical range for Change in Account Payables.
- The sharpest annual moves came in 2023 and 2024: Change in Account Payables plunged 7380.65% in 2023, then soared 5069.23% in 2024.
- Over 5 years, Change in Account Payables stood at -$468000.0 in 2021, then jumped by 91.24% to -$41000.0 in 2022, then surged by 253.66% to $63000.0 in 2023, then slumped by 1728.57% to -$1.0 million in 2024, then surged by 149.71% to $510000.0 in 2025.
- According to Business Quant data, Change in Account Payables over the past three periods registered $510000.0, $128000.0, and -$913000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -66.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -8.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 37.53 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Cibus | 129.72 Mn | 109.29 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 510,000.00 |
| Dec 31, 2025 | 510,000.00 |
| Sep 30, 2025 | 128,000.00 |
| Sep 30, 2025 | 128,000.00 |
| Jun 30, 2025 | -913,000.00 |
| Jun 30, 2025 | -913,000.00 |
| Mar 31, 2025 | 995,000.00 |
| Mar 31, 2025 | 995,000.00 |
| Dec 31, 2024 | -1.03 Mn |
| Dec 31, 2024 | -1.03 Mn |
| Sep 30, 2024 | 862,000.00 |
| Sep 30, 2024 | 862,000.00 |
| Jun 30, 2024 | -670,000.00 |
| Jun 30, 2024 | -670,000.00 |
| Mar 31, 2024 | 646,000.00 |
| Mar 31, 2024 | 646,000.00 |
| Dec 31, 2023 | 63,000.00 |
| Dec 31, 2023 | 63,000.00 |
| Sep 30, 2023 | 2.21 Mn |
| Sep 30, 2023 | 2.21 Mn |